Exor N.V. (the “Company”) announces today that it will restart the share buyback program announced on 13 September 2023 (the “Program”) for the remaining amount of up to € 250 million of ordinary shares to reduce Exor’s share capital in line with the announcement made on 13 September 2023.

The Company will start on 15 April 2024 with a first tranche of purchases up to €125 million, which is expected to complete by September 2024, or earlier if the maximum amount has been reached (the "First Tranche").

• NAV reached €35.5 billion at 31 December 2023 with NAV per share increasing by 32.7%, outperforming the MSCI World Index by 15.1 p.p.

Clarivate and Exor Sign Agreement Under Which Suzanne Heywood Will Be Nominated to Stand for Election to the Company’s Board of Directors

Exor becomes a long-term investor in Clarivate, endorsing the strategic direction set out by the Company’s Management and Board, and announces it now has a 10.1% shareholding in the Company and can increase its participation up to 17.5%

Exor N.V. announces the settlement of the previously announced offering of Euro 650 million notes priced on 7 February 2024 with a fixed annual coupon of 3.750% and due on 14 February 2033.

The notes have been listed on the Luxembourg Stock Exchange, admitted for trading on the Euro MTF Market and assigned a credit rating of A- by Standard and Poor’s rating agency.

Exor N.V. (rated A- with stable outlook by Standard & Poor’s) announces the pricing of Euro 650 million notes due on 14 February 2033, with an issue price of 99.371% and a fixed annual coupon of 3.75%.

The purpose of the issue is to raise new funds for Exor’s general corporate purposes and refinance debt maturing in 2024.

The notes will be listed on the Luxembourg Stock Exchange, admitted for trading on the Euro MTF Market, and the settlement of the issue will take place on 14 February 2024.